Jump to content

Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Simfibrate: Difference between pages

(Difference between pages)
Page 1
Page 2
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 452131714 of page Simfibrate for the Chem/Drugbox validation project (updated: '').
 
 
Line 1: Line 1:
{{Short description|Chemical compound}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Simfibrate|oldid=452131714}} 452131714] of page [[Simfibrate]] with values updated to verified values.}}
{{Drugbox
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447821664
| verifiedrevid = 464391792
| IUPAC_name = propane-1,3-diyl bis[2-(4-chlorophenoxy)-2-methylpropanoate]
| IUPAC_name = Propane-1,3-diyl bis[2-(4-chlorophenoxy)-2-methylpropanoate]
| image = simfibrate.png
| image = Simfibrate.svg


<!--Clinical data-->
<!--Clinical data-->
| tradename =
| tradename = Cholesolvin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| legal_status =
| routes_of_administration =
| routes_of_administration =


<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
| metabolism =
| metabolism =
| elimination_half-life =
| elimination_half-life =
| excretion =
| excretion =


<!--Identifiers-->
<!--Identifiers-->
| CAS_number =
| CAS_number = 14929-11-4
| ATC_prefix = C10
| ATC_prefix = C10
| ATC_suffix = AB06
| ATC_suffix = AB06
| PubChem = 5217
| PubChem = 5217
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5028
| ChemSpiderID = 5028
Line 40: Line 41:
<!--Chemical data-->
<!--Chemical data-->
| C=23 | H=26 | Cl=2 | O=6
| C=23 | H=26 | Cl=2 | O=6
| molecular_weight = 469.354 g/mol
| smiles = Clc2ccc(OC(C(=O)OCCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)(C)C)cc2
| smiles = Clc2ccc(OC(C(=O)OCCCOC(=O)C(Oc1ccc(Cl)cc1)(C)C)(C)C)cc2
| InChI = 1/C23H26Cl2O6/c1-22(2,30-18-10-6-16(24)7-11-18)20(26)28-14-5-15-29-21(27)23(3,4)31-19-12-8-17(25)9-13-19/h6-13H,5,14-15H2,1-4H3
| InChIKey = JLRNKCZRCMIVKA-UHFFFAOYAQ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H26Cl2O6/c1-22(2,30-18-10-6-16(24)7-11-18)20(26)28-14-5-15-29-21(27)23(3,4)31-19-12-8-17(25)9-13-19/h6-13H,5,14-15H2,1-4H3
| StdInChI = 1S/C23H26Cl2O6/c1-22(2,30-18-10-6-16(24)7-11-18)20(26)28-14-5-15-29-21(27)23(3,4)31-19-12-8-17(25)9-13-19/h6-13H,5,14-15H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JLRNKCZRCMIVKA-UHFFFAOYSA-N
| StdInChIKey = JLRNKCZRCMIVKA-UHFFFAOYSA-N
| synonyms = <small>3-{[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy}propyl 2-(4-chlorophenoxy)-2-methylpropanoate</small>
| synonyms = 3-<nowiki>{[</nowiki>2-(4-Chlorophenoxy)-2-methylpropanoyl]oxy}propyl 2-(4-chlorophenoxy)-2-methylpropanoate
}}
}}

'''Simfibrate''' ([[Japanese Accepted Name|JAN]]/[[International Nonproprietary Name|INN]]; trade name '''Cholesolvin''') is a [[fibrate]] that has been used for the treatment of [[hyperlipidemia]].<ref>{{Cite journal | doi = 10.22159/ijcpr.2017v9i1.16616 | title = Introduction to Hyperlipidemia and its Treatment: A Review | journal = International Journal of Current Pharmaceutical Research | volume = 9 | pages = 6 | year = 2016 | last1 = Verma | first1 = Niharika | name-list-style = vanc | doi-access = free }}</ref><ref>{{cite journal | vauthors = Olsson AG, Orö L, Rössner S | title = Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate | journal = Atherosclerosis | volume = 19 | issue = 3 | pages = 407–15 | year = 1974 | pmid = 4364073 | doi = 10.1016/S0021-9150(74)80005-5 }}</ref> The substance is a double [[ester]] of [[clofibric acid]] with [[1,3-propanediol]] which is cleaved in the body to one molecule of 1,3-propanediol and two molecules of clofibric acid which is the true [[lipid-lowering agent]].

== References ==
{{Reflist}}

{{Lipid modifying agents}}
{{PPAR modulators}}

[[Category:4-Chlorophenyl compounds]]
[[Category:2-Methyl-2-phenoxypropanoic acid derivatives]]

{{cardiovascular-drug-stub}}